RIPK3 and type 2 diabetes mellitus: As shown in Fig 2E, anti-TNFR1 antibody treatment significantly reduced the expression of RIPK3, MLKL and IL-6 compared to isotype control antibody in T2DM mouse alveolar macrophages infected with Mtb.